Cergutuzumab amunaleukin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Cergutuzumab amunaleukin (CEA-IL2v) 是一种基于癌胚抗原 (CEA) 靶向 IL-2 变体的免疫细胞因子。Cergutuzumab amunaleukin 具有免疫刺激和抗肿瘤活性。

Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities.

Cergutuzumab amunaleukin comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent CEA-specific antibody devoid of Fc-mediated effector functions. Its molecular design aims to avoid preferential activation of regulatory T-cells vs. immune effector cells by removing CD25 binding. The activation of NK cells by Cergutuzumab amunaleukin (CEA-IL2v; 0.001-1000 nM) translated into increased killing of the CEA-positive colon cancer cell line LS180 accompanied by increased release of Granzyme B, IFNγ and RANTES and upregulation of CD25 and CD69 on NK cells..

In tumor-free mice, a strong expansion of peripheral CD8+ T and NK cells after treatment with 0.5 and 2 mg/kg Cergutuzumab amunaleukin (CEA-IL2v;i.v.; once) is observed.

——

Others

Other Targets

Interleukin

——

——

1509916-03-3

162.05 kDa

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years